GlobalData on MSN1mon
FDA approves Roche’s Tecentriq Hybreza for cancerThe US Food and Drug Administration (FDA) has approved Roche's Tecentriq Hybreza, a subcutaneous anti-PD-(L)1 cancer ...
Bevacizumab in combination with atezolizumab and chemotherapy led to improvements in progression-free survival and duration ...
Zacks.com on MSN1mon
Roche Gets FDA Approval for Subcutaneous Formulation of TecentriqEstimates for Eli Lilly’s 2024 earnings have risen from $15.77 to $16.49 per share over the past 30 days. For 2025, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback